Published March 2015

The objective of this guideline is to delineate optimal diagnostic and therapeutic approaches to congenital muscular dystrophy (CMD) through a systematic review and analysis of the currently available literature. Reaffirmed on July 12, 2024. Co-developed with the American Association of Neuromuscu

Published April 2017

The goal of this practice guideline is to examine evidence for the SUDEP incidence rate in epilepsy populations and for prognostic factors for SUDEP occurrence. This in turn will inform an honest and balanced discussion when clinicians counsel people about SUDEP, and provide insight into areas where

Published January 2003

The objective of this practice parameter was to review the evidence regarding antiepileptic drug (AED) prophylaxis in patients with severe traumatic brain injury (TBI) in order to make practice recommendations. Reaffirmed on October 19, 2024.

Published August 2019

The purpose of this guideline is to systematically assess all randomized controlled trials (RCTs) that evaluated acute migraine treatments in children and adolescents. The guideline seeks to answer the following clinical question: In children and adolescents with migraine, do acute self-administered

Published August 2019

This guideline systematically evaluates new evidence to answer the following clinical question: In children and adolescents with migraines, do preventive pharmacologic treatments, with or without cognitive behavioral therapy (CBT), compared with placebo, reduce headache frequency? Reaffirmed on Oct

Published March 2003

This article addresses published evidence on the safety and efficacy of localized resective surgery, either temporal or neocortical, as treatment for uncontrolled complex partial seizures. Reaffirmed on July 16, 2022.

Published August 2002

For this parameter, the authors reviewed available evidence on the evaluation of the child with recurrent headaches and made recommendations based on this evidence. Reaffirmed on July 16, 2022.

Published June 2018

This is an update to the 2004 American Academy of Neurology (AAN) guideline for treating new-onset focal or generalized epilepsy with second- and third-generation antiepileptic drugs (AEDs). This update reviews new evidence for efficacy, safety, and tolerability of CLB, VGB, and the 8 second-generat

Published January 2003

This practice parameter reviews the current evidence about treatment with AED after a child experiences a first unprovoked seizure. Reaffirmed on July 12, 2024.

Published September 2003

This practice parameter classifies the relevant evidence on immunotherapy to provide evidence-based recommendations for the management of GBS. Reaffirmed on January 22, 2022.

Published September 2000

For this practice parameter, the authors reviewed available evidence on evaluation of the first nonfebrile seizure in children in order to make practice recommendations based on this available evidence. Last reaffirmed on October 21, 2023.

Published March 2013

This evidence-based guideline replaces the 1997 American Academy of Neurology (AAN) practice parameter on the management of sports concussion. It reviews the evidence published since 1955 regarding the evaluation and management of sports concussion in children, adolescents, and adults. Reaffirmed o

Published February 2020

Autism spectrum disorders (ASD) are complex neurodevelopmental disorders characterized by social interaction/communication challenges and restrictive, stereotyped behavior patterns. Sleep disturbances in ASD are common. This guideline addresses the following question: In children and adolescents wit

Published December 2021

This practice advisory update reviews the risks and benefits of discontinuing antiseizure medication use in seizure-free patients. According to the practice advisory, people with epilepsy who have been seizure-free (two years for adults and 1.5 to two years for children/adolescents) and stop use of

Published May 2019

The authors of the practice guideline seek to make recommendations, based on evidence identified from the systematic review, general principles of care, and related evidence, regarding the following questions: 1. In children and adults with TS or a chronic tic disorder, when should clinicians and pa

Published November 2006

This Practice Parameter reviews available evidence concerning the value of diagnostic testing in children and adolescents with SE and provides recommendations based upon this evidence. Treatment guidelines are not included but are under development. Reaffirmed on January 22, 2022.

Published June 2018

Since the 2004 publications, the US Food and Drug Administration (FDA) approved 6 new third-generation AEDs and 2 older AEDs. This update reviews new evidence for efficacy of these AEDs in managing treatment-resistant (TR) focal epilepsies and generalized epilepsies (GEs) in children and adults. Re

Published August 2013

The objective of this guideline is to evaluate the evidence since the 1999 assessment regarding efficacy and safety of vagus nerve stimulation (VNS) for epilepsy, currently approved as adjunctive therapy for partial-onset seizures in patients >12 years. Reaffirmed on July 16, 2022. Endorsed by the

Published February 2016

A 2005 American Academy of Neurology (AAN) guideline on the use of corticosteroids in patients with Duchenne muscular dystrophy (DMD) recommended prednisone or deflazacort in the treatment of DMD for short-term benefit in muscle strength and function. There are currently variations in practice in co

Published January 2010

This article reviews and evaluates published evidence of the efficacy and safety of these medications in children and adolescents affected by spasticity due to CP. Reaffirmed on July 16, 2022.